IonQ

IonQ is a leader in trapped-ion quantum computing, publicly traded on NYSE (IONQ). In 2025, the company secured landmark funding including a $2 billion institutional investment and completed a $1 billion equity offering, bringing cash position to $1.6 billion. Q3 2025 revenue reached $39.9 million (+221.5% YoY), with FY 2025 guidance of $106-110 million.

December 2025: Through subsidiary ID Quantique, deployed Slovakia's first national quantum communication network (skQCI) as part of the EU-wide EuroQCI initiative, connecting the Presidential Palace, National Security Authority, and Slovak Academy of Sciences. Also announced strategic quantum-biotech partnership with CCRM to accelerate next-generation therapeutic development. Invested in Horizon Quantum Computing's $110M PIPE financing alongside Fortune 50 technology companies.

The company executed an aggressive M&A strategy in 2024-2025 totaling ~$2.5 billion across 7+ acquisitions: Oxford Ionics ($1.075B - trapped-ion technology), ID Quantique ($250M - quantum networking), Capella Space ($318M - satellite imaging), Vector Atomic (atomic clocks/inertial sensors), Qubitekk (quantum networking), Skyloom Global (optical communications), and Lightsynq Technologies (entanglement distribution). This positions IonQ for full-stack quantum-to-space capabilities.

Major contracts include $54.5 million from US Air Force Research Lab. IonQ achieved world-record 99.99% two-qubit gate fidelity and #AQ 64 on its Tempo system. Named only quantum company in Deloitte's 2025 Technology Fast 500 (nearly 2000% revenue growth 2021-2024). November 2025: CEO Niccolo de Masi testified to Congress that IonQ's commercial era has begun. Roadmap targets CRQC by 2028 (~20,000 physical qubits) and ~2 million physical qubits by 2030. Launched Geneva Quantum Network (GQN) with Swiss consortium (UNIGE, CERN, Rolex SA).

Key partnerships include CCRM (biotech), Heven AeroTech (strategic investor, $100M Series B), General Dynamics IT, SK Telecom, AstraZeneca, Ansys, Classiq, and Horizon Quantum. Focus areas: defense, government, enterprise, healthcare, and biotech sectors.